link to paper Hanemaaijer S, Kok I, Fehrmann RSN, van der Vegt B, Gietema J, Plaat B, van Vugt MATM, Vergeer M, Leemans RC, Langendijk JA, Voortman J, Buter J, Oosting JF. Background: Chemoradiotherapy (CRT) including three cycles of cisplatin is considered the standard of care for locally advanced head and neck squamous cell carcinoma…

Link to paper Workel HH, van Rooij N, Plat A, Spierings DCJ, Fehrmann RSN, Nijman HW. de Bruyn M Abstract: Tumor-infiltrating CD8+ T cells (TIL) are of the utmost importance in anti-tumor immunity. CD103 defines tumor-resident memory T cells (TRM cells) associated with improved survival and response to immune checkpoint blockade (ICB) across human tumors. Co-expression…

Link to paper Knapen DJ, Kwee TC, Meijne EIM, Fehrmann RSN, de Vries EGE AbstractImmune checkpoint inhibitors (ICI) have improved outcomes for patients with advanced cancers, and results in increasing numbers of long-term survivors. For registration studies, progression-free survival and disease-free survival often serve as primary endpoints. This requires repeated computed tomography (CT) scans for…

Link to paper Boonstra PA, Wind TT, van Kruchten M, Schuuring E, Hospers GAP, van der Wekken AJ, de Groot DJ, Schröder CP, Fehrmann RSN, Reyners AKL AbstractResponse evaluation for cancer treatment consists primarily of clinical and radiological assessments. In addition, a limited number of serum biomarkers that assess treatment response are available for a…

Link to paper Bhattacharya A, Bense RD, Urzúa-Traslaviña CG, de Vries EGE, van Vugt MATM, Fehrmann RSN AbstractCopy number alterations (CNAs) can promote tumor progression by altering gene expression levels. Due to transcriptional adaptive mechanisms, however, CNAs do not always translate proportionally into altered expression levels. By reanalyzing >34,000 gene expression profiles, we reveal the…

Link to paper van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, Brouwers AH, van der Wekken AJ, Oosting SF, Fehrmann RSN, de Groot DJA, de Vries EGE Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the…

Link to paper J.S. Hooiveld-Noeken, R.S.N. Fehrmann, E.G.E. de Vries, M. Jalving Highlights • Metastatic Merkel- and cutaneous squamous cell carcinoma are rare tumours. • Immunotherapy gives impressive responses but most patients do not survive long-term. • Small patients numbers prevent extensive biomarker research in clinical trials. • Pooled data from common and rare tumours…

Link to paper Peters MAM, Meijer C, Fehrmann RSN, Walenkamp AME, Kema IP, de Vries EGE, Hollema H, Oosting SF. Abstract In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set…

Link to paper Bouwstra R, He Y, de Boer JW, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T. Abstract Addition of rituximab (R) to “CHOP” (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients that…

Link to paper Venema CM, Bense RD, Steenbruggen TG, Nienhuis HH, Qiu SQ, van Kruchten M, Brown M, Tamimi RM, Hospers GAP, Schröder CP, Fehrmann RSN, de Vries EGE. Abstract The androgen receptor (AR) is a drug target in breast cancer, and AR-targeted therapies have induced tumor responses in breast cancer patients. In this review,…